Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 5/20 | 0.74 |
| ▸ | BCOR | Q6W2J9 | 5/20 | 0.74 |
| ▸ | GAA | P10253 | 8/20 | 0.46 |
| ▸ | GFER | P55789 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 9/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20772501 | 0.90 | BCL6 (0.71) | BCL6BCORGAAMAPTKDM4E | |
| SCHEMBL20773006 | 0.85 | BCL6 (0.57) | BCL6BCORGAAGFERNPC1 | |
| SCHEMBL30832798 | 0.85 | BCL6 (0.57) | BCL6BCORGAAGFERNPC1 | |
| SCHEMBL29280286 | 0.84 | BCL6 (0.72) | BCL6BCORGAAMAPTKDM4E | |
| SCHEMBL20772931 | 0.81 | BCL6 (0.69) | BCL6BCORGAAMAPTSMN1; SMN2 | |
| SCHEMBL474689 | 0.80 | BCL6 (0.64) | BCL6BCORGAANPC1MAPT | |
| SCHEMBL14179046 | 0.79 | BCL6 (0.65) | BCL6BCORGAANPC1MAPT | |
| SCHEMBL9683164 | 0.78 | GAA (0.70) | GAAGFERNPC1MAPTKDM4E | |
| SCHEMBL12374632 | 0.78 | MAPT (0.74) | GAAGFERNPC1MAPTKDM4E | |
| SCHEMBL20772687 | 0.77 | BCL6 (0.57) | BCL6BCORMAPTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111278815-A | Glutarimide | C4医药公司 | 2020-06-12 | — | — | CN | claimed |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240199638-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| CN-118206529-A | Dihydrobenzimidazolone | C4医药公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118108706-A | Glutarimide | C4医药公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| CN-111278815-B | Glutarimide | C4医药公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-111315735-B | Dihydrobenzimidazolone | C4医药公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11802131-B2 | Glutarimides for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11254672-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254672-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3679027-A1 | DIHYDROBENZIMIDAZOLONES | C4 Therapeutics, Inc. (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200207783-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200207764-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200207764-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| CN-111315735-A | Dihydrobenzimidazolones | C4医药公司 | 2020-06-19 | — | — | CN | disclosed |
| CN-111278815-A | Glutarimide | C4医药公司 | 2020-06-12 | — | — | CN | disclosed |
| WO-2019043217-A1 | DIHYDROBENZIMIDAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019043217-A1 | DIHYDROBENZIMIDAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207764-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | BCL6 427/4885BCOR 103/4885GAA 1982/4885 |
| US-11802131-B2 | Glutarimides for medical treatment | CRBN, GCDH, GCLC | BCL6 463/4885BCOR 336/4885GAA 742/4885 |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | BCL6 427/4885BCOR 103/4885GAA 1982/4885 |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | BCL6 427/4885BCOR 103/4885GAA 1982/4885 |
| US-20240199638-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | CRBN, GCDH, GCLC | BCL6 463/4885BCOR 336/4885GAA 742/4885 |
| US-20200207783-A1 | GLUTARIMIDES FOR MEDICAL TREATMENT | CRBN, GCDH, GCLC | BCL6 463/4885BCOR 336/4885GAA 742/4885 |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | BCL6 427/4885BCOR 103/4885GAA 1982/4885 |
| US-11254672-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | BCL6 427/4885BCOR 103/4885GAA 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.